Department of Allergy, Zhongnan Hospital of Wuhan University, Wuhan, China.
Department of Clinical Laboratory, Zhongnan Hospital of Wuhan University, Wuhan, China.
J Clin Pharm Ther. 2019 Jun;44(3):486-488. doi: 10.1111/jcpt.12827. Epub 2019 Mar 11.
Omalizumab is effective as an add-on drug to treat severe persistent allergic asthma. However, delayed hypersensitivity reactions to omalizumab may deprive patients of its use. Rapid subcutaneous desensitization could be a solution.
A 61-year-old man developed a delayed allergy to omalizumab after the first injection. A 14-step desensitization procedure was applied to the patient and was successful.
Delayed hypersensitivity reactions to omalizumab are rare, but they may cause the interruption of drug usage. Desensitization to omalizumab could be a possible solution.
奥马珠单抗作为一种附加药物治疗严重持续性过敏性哮喘是有效的。然而，奥马珠单抗的迟发性过敏反应可能会使患者无法使用该药。快速皮下脱敏可能是一种解决方案。
一名 61 岁男性在第一次注射后出现奥马珠单抗迟发性过敏。对患者进行了 14 步脱敏程序，并且成功了。
奥马珠单抗的迟发性过敏反应罕见，但可能导致药物中断。奥马珠单抗脱敏可能是一种可行的解决方案。
